AIDS, HIV, Smoking Cessation
Conditions
Brief summary
To determine the efficacy of an algorithm designed to recommend smoking cessation-related pharmacotherapy options to the primary care providers of smokers living with HIV/AIDS.
Detailed description
Smoking remains the leading cause of preventable death and disability in the United States. Whereas smoking has declined significantly among individuals in the general population, it is clustered in populations of vulnerable individuals such as people living with HIV/AIDS (PLWH) in whom smoking prevalence rates and resulting comorbidity rates remain high. Medical advances in the treatment of HIV have resulted in substantial increases in life expectancy among PLWH and as a consequence PLWH smokers are now, more than ever, at heightened risk for tobacco-related illnesses and death. PLWH smokers engaged in treatment lose more years of life due to smoking now than to HIV disease. Although PLWH smokers engaged in HIV care typically see a medical provider every 4-6 months, smoking cessation treatment and referral is often not part of routine HIV care. While 94% of HIV treatment providers indicated that they would be willing to provide smoking cessation services to their patients, few have received training in how to provide smoking cessation services. With seven first line pharmacotherapies available for smoking cessation, development of algorithms to assist providers in selecting the most appropriate pharmacotherapy is an important but untested strategy to increase smoking cessation in PLWH. The purpose of this proposal is to conduct a mixed efficacy/effectiveness trial comparing an algorithm treatment with prescription cost off sets and quit line referral (AT) to an enhanced Treatment as Usual (quit line referral only; eTAU) group. Six hundred PLWH smokers will be recruited at the University of Alabama at Birmingham, University of Washington, and Fenway Health HIV clinics and will be randomized to receive AT or eTAU. All AT smokers will receive active treatment for twelve weeks regardless of stated motivation or intention to quit. eTAU smokers will be referred to quit line services and HIV providers may elect to treat smoking as part of standard of care. Participants will remain in the study for 12 months.
Interventions
DRUGAlgorithm Treatment
Varenicline was selected as the first line of treatment for patients willing to take a medication twice per day and wanting cessation. Following varenicline, bupropion and then NRT are subsequent options. In terms of preference for NRT, nicotine patches would be the first option followed by lozenge, gum, inhaler, and nasal spray. The order of NRT within the algorithm is based upon patient familiarity and number of clinical trials supporting their use. Combination NRT (e.g., patch and lozenge) or adding NRT to varenicline or bupropion is offered to participants who have made an unsuccessful quit attempt with these medications in the past. If none of these medications are appropriate, then the participant is offered counseling only.
OTHERQuitline only
eTAU participants will complete the same algorithm questions but will not have this information sent to their provider, although their provider may elect to prescribe medication as part of standard of care. Participants will be referred to a quitline for behavioral support services for cessation.
Sponsors
University of Alabama at Birmingham
University of Washington
Harvard University
National Institute on Drug Abuse (NIDA)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Participants will be randomized to either the Algorithm Treatment plus referral to a quitline (AT) or the quitline alone condition (eTAU).
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Enrollment in the CNICS clinical cohort. 2. 18 years or older; 3. Receiving HIV care at the UAB, UW or Fenway Health clinics and not anticipating changing clinics over the next six months 4. Smoking greater than or equal to 5 cigarettes per day (cpd) for the past month 5. Living in an unrestricted environment that allows smoking.
Exclusion criteria
1. Cognitive impairment such that unable to provide informed consent; 2. Non-English speaking; 3. Acutely suicidal, manic, acutely intoxicated, or otherwise not stable enough to provide informed consent; 4. Currently receiving smoking cessation treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 7-day Point-prevalence Abstinence | 6 months | Self-report of cigarette smoking in the last 7 days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cigarettes Per Day | 6 months | Number of cigarettes reported being smoked per day |
| Number of Participants Who Attempt to Not Smoke for 24-Hours at 6 Months | 6 months | Attempt to not smoke for 24 hours |
| Number of Prescriptions Written by 6-months | 6 months | The count of participants who had a smoking cessation prescription written |
Countries
United States
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 49.2 years STANDARD_DEVIATION 11.16 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 7 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 168 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 4 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants |
| Race (NIH/OMB) Asian | 4 Participants |
| Race (NIH/OMB) Black or African American | 190 Participants |
| Race (NIH/OMB) More than one race | 5 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 13 Participants |
| Race (NIH/OMB) White | 157 Participants |
| Sex: Female, Male Female | 35 Participants |
| Sex: Female, Male Male | 149 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 4 / 186 | 3 / 184 |
| other Total, other adverse events | 0 / 186 | 5 / 184 |
| serious Total, serious adverse events | 0 / 186 | 0 / 184 |
Outcome results
None listed